MarketPR
Virax Biolabs' fiscal 2026 annual report, filed July 2, 2026, shows cash of $6.4 million, total assets of $8.3 million, and shareholders' equity attributable to ordinary shareholders of $7.3 million.
One week later, on July 9, the company announced a commercial supply agreement with Fosun Diagnostics to support commercial execution for ImmuneSelect.
CEO James Foster addressed shareholders on both developments in a combined update. The balance sheet print The July 2 filing gives the market a clean read on where Virax Biolabs stands.
Total assets reach $8.3 million, with the gap between that number and the $7.3 million in shareholders' equity attributable to ordinary shareholders reflecting liabilities on the books.
Keep reading